Skip to main content
SpringerLink
Log in

Onconephrology

  • Living reference work entry
  • First Online:
Pediatric Nephrology

  • 33 Accesses

Abstract

Pediatric oncology patients are at risk for both acute and chronic kidney injury, not only from the cancer itself, but often related to its treatment. Chemotherapy, radiation, medications, infections, hematopoietic stem cell transplant, and newer therapies like CART cells and immune checkpoint inhibitors are beneficial in treating this at-risk population, but also contribute to the risk of kidney injury. Treatment advances in oncology have markedly improved outcomes, with these advances leading to a greater incidence and prevalence of kidney disease in cancer patients. This chapter addresses major nephrology issues affecting the pediatric cancer patient, focusing on acute and chronic management of kidney dysfunction. Within these realms, specific attention is given to kidney injury due to (1) primary oncologic disease, (2) established and emerging treatments, and (3) hematopoietic stem cell transplant. This chapter provides a foundation for the approach to patients that are within the realm of onconephrology, an evolving and expanding field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Park PG, Hong CR, Kang E, Park M, Lee H, Kang HJ, et al. Acute kidney injury in pediatric cancer patients. J Pediatr. 2019;208:243.e3–50.e3.

    Article  Google Scholar 

  2. Nehus EJ, Laskin BL, Kathman TI, Bissler JJ. Performance of cystatin C-based equations in a pediatric cohort at high risk of kidney injury. Pediatr Nephrol. 2013;28(3):453–61.

    Article  PubMed  Google Scholar 

  3. Blufpand HN, Tromp J, Abbink FC, Stoffel-Wagner B, Bouman AA, Schouten-van Meeteren AY, et al. Cystatin C more accurately detects mildly impaired renal function than creatinine in children receiving treatment for malignancy. Pediatr Blood Cancer. 2011;57(2):262–7.

    Article  PubMed  Google Scholar 

  4. Ng DK, Schwartz GJ, Warady BA, Furth SL, Munoz A. Relationships of measured Iohexol GFR and estimated GFR with CKD-related biomarkers in children and adolescents. Am J Kidney Dis. 2017;70(3):397–405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Laskin BL, Hingorani SR. Hypertension in oncology and stem-cell transplant patients. In: Flynn JT, Ingelfinger JR, Redwine K, editors. Pediatric hypertension. Cham: Springer; 2018. p. 629–50.

    Chapter  Google Scholar 

  6. Masetti R, Cordelli DM, Zama D, Vendemini F, Biagi C, Franzoni E, et al. PRES in children undergoing hematopoietic stem cell or solid organ transplantation. Pediatrics. 2015;135(5):890–901.

    Article  PubMed  Google Scholar 

  7. Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, et al. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2011;46(5):682–9.

    Article  CAS  PubMed  Google Scholar 

  8. Pao E, Gove NE, Flynn JT, Hingorani S. Ambulatory blood pressure and endothelial dysfunction in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24(8):1678–84.

    Article  PubMed  Google Scholar 

  9. Chapman T, Bodmer N, Benkeser DC, Hingorani SR, Parisi MT. Transient renal enlargement in pediatric hematopoietic cell transplant recipients. Pediatr Transplant. 2014;18(3):288–93.

    Article  PubMed  Google Scholar 

  10. Chang A, Hingorani S, Kowalewska J, Flowers ME, Aneja T, Smith KD, et al. Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature. Clin J Am Soc Nephrol. 2007;2(5):1014–23.

    Article  PubMed  Google Scholar 

  11. Varnell CD Jr, Stone HK, Welge JA. Bleeding complications after pediatric kidney biopsy: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2019;14(1):57–65.

    Article  PubMed  Google Scholar 

  12. Didsbury MS, Mackie FE, Kennedy SE. A systematic review of acute kidney injury in pediatric allogeneic hematopoietic stem cell recipients. Pediatr Transplant. 2015;19(5):460–70.

    Article  PubMed  Google Scholar 

  13. Salahudeen AK, Doshi SM, Pawar T, Nowshad G, Lahoti A, Shah P. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol. 2013;8(3):347–54.

    Article  PubMed  Google Scholar 

  14. Basu RK, Zappitelli M, Brunner L, Wang Y, Wong HR, Chawla LS, et al. Derivation and validation of the renal angina index to improve the prediction of acute kidney injury in critically ill children. Kidney Int. 2014;85(3):659–67.

    Article  PubMed  Google Scholar 

  15. Coca A, Aller C, Reinaldo Sanchez J, Valencia AL, Bustamante-Munguira E, Bustamante-Munguira J. Role of the furosemide stress test in renal injury prognosis. Int J Mol Sci. 2020;21(9):3086.

    Article  CAS  PubMed Central  Google Scholar 

  16. Rossi R, Kleta R, Ehrich JH. Renal involvement in children with malignancies. Pediatr Nephrol. 1999;13(2):153–62.

    Article  CAS  PubMed  Google Scholar 

  17. Hanna WT, Krauss S, Regester RF, Murphy WM. Renal disease after mitomycin C therapy. Cancer. 1981;48(12):2583–8.

    Article  CAS  PubMed  Google Scholar 

  18. Lopez-Beltran A, Luque RJ, Mazzucchelli R, Scarpelli M, Montironi R. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J Clin Pathol. 2002;55(9):641–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer. 1985;55(1):47–50.

    Article  CAS  PubMed  Google Scholar 

  20. Leal F, Macedo LT, Carvalheira JB. Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series. J Chemother. 2014;26(3):169–72.

    Article  CAS  PubMed  Google Scholar 

  21. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Glezerman IG, Jaimes EA. Chemotherapy and kidney injury. 2016. In: Onco-Nephrology [Internet]. https://www.asn-online.org/education/distancelearning/curricula/onco/: ASN online Curricula; [1–10].

  23. Grillo F, Florio T, Ferrau F, Kara E, Fanciulli G, Faggiano A, et al. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Endocr Relat Cancer. 2018;25(9):R453–R66.

    Article  PubMed  Google Scholar 

  24. Syed U, Wahlberg KJ, Douce DR, Sprague JR. Thrombotic thrombocytopenic purpura associated with pazopanib. Case Rep Hematol. 2018;2018:4327904.

    PubMed  PubMed Central  Google Scholar 

  25. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(11):2471–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7(10):1713–21.

    Article  CAS  PubMed  Google Scholar 

  27. Skinner R, Cotterill S, Stevens M. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. Br J Cancer. 2000;82(10):1636.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Hempel L, Misselwitz J, Fleck C, Kentouche K, Leder C, Appenroth D, et al. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol. 2003;40(6):348–54.

    Article  PubMed  Google Scholar 

  29. Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma: incidence, treatment, and outcome. Cancer. 2004;100(10):2222–32.

    Article  CAS  PubMed  Google Scholar 

  30. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694–703.

    Article  CAS  PubMed  Google Scholar 

  31. Emi Fujikura MA, Miyauchi K, Yoshida M, Aoki S, Yamamoto T, Narumi K, Yanagisawa N, Nakamichi T, Miyazaki M, Sato H, Ito S. Blood purification therapies in methotrexate-induced acute kidney injury: four case reports. Renal Replace Ther. 2017;3:1–6.

    Google Scholar 

  32. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115–24.

    Article  PubMed  Google Scholar 

  33. Kimura T, Ozawa T, Hanai N, Hirakawa H, Suzuki H, Hosoi H, et al. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer. J Otolaryngol Head Neck Surg. 2018;47(1):10.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Stöhr W, Paulides M, Bielack S, Jürgens H, Koscielniak E, Rossi R, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer. 2007;48(2):140–7.

    Article  PubMed  Google Scholar 

  35. Sleijfer D, Smit E, Meijer S, Mulder N, Postmus P. Acute and cumulative effects of carboplatin on renal function. Br J Cancer. 1989;60(1):116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Perazella MA, Sprangers B. AKI in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(7):1077–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Izzedine H, Gueutin V, Gharbi C, Mateus C, Robert C, Routier E, et al. Kidney injuries related to ipilimumab. Investig New Drugs. 2014;32(4):769–73.

    Article  CAS  Google Scholar 

  38. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361(2):211–2.

    Article  CAS  PubMed  Google Scholar 

  39. Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney Int. 2015;87(5):909–17.

    Article  CAS  PubMed  Google Scholar 

  40. Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Renal effects of targeted anticancer therapies. Nat Rev Nephrol. 2015;11(6):354.

    Article  CAS  PubMed  Google Scholar 

  41. Rosner MH, Perazella MA. Acute kidney injury in patients with cancer. N Engl J Med. 2017;376(18):1770–81.

    Article  CAS  PubMed  Google Scholar 

  42. Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O’Donnell EK, Jacobson CA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am J Kidney Dis. 2020;76(1):63–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M, et al. Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol Blood Marrow Transplant. 2020;26(6):1071–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lange J, Peterson SM, Takashima JR, Grigoriev Y, Ritchey ML, Shamberger RC, et al. Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor. J Urol. 2011;186(2):378–86.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Cozzi DA, Ceccanti S, Frediani S, Mele E, Cozzi F. Renal function adaptation up to the fifth decade after treatment of children with unilateral renal tumor: a cross-sectional and longitudinal study. Pediatr Blood Cancer. 2013;60(9):1534–8.

    Article  PubMed  Google Scholar 

  46. Dekkers IA, Blijdorp K, Cransberg K, Pluijm SM, Pieters R, Neggers SJ, et al. Long-term nephrotoxicity in adult survivors of childhood cancer. Clin J Am Soc Nephrol. 2013;8(6):922–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Knijnenburg SL, Jaspers MW, van der Pal HJ, Schouten-van Meeteren AY, Bouts AH, Lieverst JA, et al. Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol. 2012;7(9):1416–27.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Welch TR, McAdams AJ. Focal glomerulosclerosis as a late sequela of Wilms tumor. J Pediatr. 1986;108(1):105–9.

    Article  CAS  PubMed  Google Scholar 

  49. Breslow NE, Collins AJ, Ritchey ML, Grigoriev YA, Peterson SM, Green DM. End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol. 2005;174(5):1972–5.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Bailey S, Roberts A, Brock C, Price L, Craft A, Kilkarni R, et al. Nephrotoxicity in survivors of Wilms’ tumours in the North of England. Br J Cancer. 2002;87(10):1092.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Ritchey ML, Green DM, Thomas PR, Smith GR, Haase G, Shochat S, et al. Renal failure in Wilms’ tumor patients: a report from the National Wilms’ Tumor Study Group. Med Pediatr Oncol. 1996;26(2):75–80.

    Article  CAS  PubMed  Google Scholar 

  52. Edeani ACE. Radation nephropathy. 2016. In: Onco-Nephrology [Internet]. https://www.asn-online.org/education/distancelearning/curricula/onco/. [1–6].

  53. De Graaf S, Van Gent H, Reitsma-Bierens WCC, Van Luyk W, Dolsma W, Postma A. Renal function after unilateral nephrectomy for Wilms’ tumour: the influence of radiation therapy. Eur J Cancer. 1996;32(3):465–9.

    Article  Google Scholar 

  54. Hingorani S. Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol. 2006;17(7):1995–2005.

    Article  PubMed  Google Scholar 

  55. Watanabe Nemoto M, Isobe K, Togasaki G, Kanazawa A, Kurokawa M, Saito M, et al. Delayed renal dysfunction after total body irradiation in pediatric malignancies. J Radiat Res. 2014;55(5):996–1001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Hingorani S. Chronic kidney disease after pediatric hematopoietic cell transplant. Biol Blood Marrow Transplant. 2008;14(1):84–7.

    Article  PubMed  Google Scholar 

  57. Touzot M, Elie C, van Massenhove J, Maillard N, Buzyn A, Fakhouri F. Long-term renal function after allogenic haematopoietic stem cell transplantation in adult patients: a single-centre study. Nephrol Dial Transplant. 2010;25(2):624–7.

    Article  PubMed  Google Scholar 

  58. Group CsO. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Monrovia. 2018. https://www.survivorshipguidelines.org

  59. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11.

    Article  PubMed  Google Scholar 

  60. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med. 1993;94(2):133–9.

    Article  CAS  PubMed  Google Scholar 

  61. Cairo MS, Coiffier B, Reiter A, Younes A, Panel TLSE. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86.

    Article  CAS  PubMed  Google Scholar 

  62. Spinale JM, Laskin BL, Sondheimer N, Swartz SJ, Goldstein SL. High-dose continuous renal replacement therapy for neonatal hyperammonemia. Pediatr Nephrol. 2013;28(6):983–6.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379(9823):1301–9.

    Article  CAS  PubMed  Google Scholar 

  64. Hopps SA, Borders EB, Hagemann TM. Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature. J Oncol Pharm Pract. 2016;22(3):496–510.

    Article  CAS  PubMed  Google Scholar 

  65. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44(6):778–83.

    Article  CAS  PubMed  Google Scholar 

  66. Kammersgaard MB, Kielsen K, Heilmann C, Ifversen M, Muller K. Assessment of the proposed EBMT pediatric criteria for diagnosis and severity grading of sinusoidal obstruction syndrome. Bone Marrow Transplant. 2019;54(9):1406–18.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53(2):138–45.

    Article  CAS  PubMed  Google Scholar 

  68. Rio B, Andreu G, Nicod A, Arrago JP, Dutrillaux F, Samama M, et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood. 1986;67(6):1773–6.

    Article  CAS  PubMed  Google Scholar 

  69. Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124(4):645–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A, et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant. 2009;15(1):101–8.

    Article  CAS  PubMed  Google Scholar 

  71. Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010;115(5):1098–105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Hingorani S. Renal complications of hematopoietic-cell transplantation. N Engl J Med. 2016;374(23):2256–67.

    Article  PubMed  Google Scholar 

  73. Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122(12):2003–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Ardissino G, Salardi S, Berra S, Colussi G, Cugno M, Zecca M, et al. Acquired complement regulatory gene mutations and hematopoietic stem cell transplant-related thrombotic microangiopathy. Biol Blood Marrow Transplant. 2017;23(9):1580–2.

    Article  CAS  PubMed  Google Scholar 

  75. Jodele S, Dandoy CE, Myers K, Wallace G, Lane A, Teusink-Cross A, et al. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. Bone Marrow Transplant. 2018;53(10):1311–8.

    Article  CAS  PubMed  Google Scholar 

  76. Mii A, Shimizu A, Kaneko T, Fujita E, Fukui M, Fujino T, et al. Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Pathol Int. 2011;61(9):518–27.

    Article  PubMed  Google Scholar 

  77. Peyvandi F, Siboni SM, Lambertenghi Deliliers D, Lavoretano S, De Fazio N, Moroni B, et al. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. Br J Haematol. 2006;134(2):187–95.

    Article  CAS  PubMed  Google Scholar 

  78. Hingorani S, Finn LS, Pao E, Lawler R, Schoch G, McDonald GB, et al. Urinary elafin and kidney injury in hematopoietic cell transplant recipients. Clin J Am Soc Nephrol. 2015;10(1):12–20.

    Article  CAS  PubMed  Google Scholar 

  79. Grimaldi F, Potter V, Perez-Abellan P, Veluchamy JP, Atif M, Grain R, et al. Mixed T cell chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia using an alemtuzumab-containing regimen is shaped by persistence of recipient CD8 T cells. Biol Blood Marrow Transplant. 2017;23(2):293–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Daraskevicius J, Azukaitis K, Dziugeviciute-Tupko J, Peciulyte M, Planciunaite R, Vaitkeviciene G, et al. Phenotypes and baseline risk factors of acute kidney injury in children after allogeneic hematopoietic stem cell transplantation. Front Pediatr. 2020;8:499.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Hingorani SR, Seidel K, Lindner A, Aneja T, Schoch G, McDonald G. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transplant. 2008;14(12):1365–72.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Beyar-Katz O, Davila EK, Zuckerman T, Fineman R, Haddad N, Okasha D, et al. Adult nephrotic syndrome after hematopoietic stem cell transplantation: renal pathology is the best predictor of response to therapy. Biol Blood Marrow Transplant. 2016;22(6):975–81.

    Article  PubMed  Google Scholar 

  83. Patzer L, Kentouche K, Ringelmann F, Misselwitz J. Renal function following hematological stem cell transplantation in childhood. Pediatr Nephrol. 2003;18(7):623–35.

    Article  PubMed  Google Scholar 

  84. Rajpal JS, Patel N, Vogel RI, Kashtan CE, Smith AR. Improved survival over the last decade in pediatric patients requiring dialysis after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(4):661–5.

    Article  PubMed  Google Scholar 

  85. Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sørensen HT. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med. 2011;22(4):399–406.

    Article  PubMed  Google Scholar 

  86. Raymakers-Janssen PA, Lilien MR, Tibboel D, Kneyber MC, Dijkstra S, van Woensel JB, et al. Epidemiology and outcome of critically ill pediatric cancer and hematopoietic stem cell transplant patients requiring continuous renal replacement therapy: a Retrospective Nationwide Cohort study. Crit Care Med. 2019;47(11):e893.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Sutherland SM, Zappitelli M, Alexander SR, Chua AN, Brophy PD, Bunchman TE, et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis. 2010;55(2):316–25.

    Article  PubMed  Google Scholar 

  88. Walters S, Porter C, Brophy PD. Dialysis and pediatric acute kidney injury: choice of renal support modality. Pediatr Nephrol. 2009;24(1):37–48.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Kwiatkowski DM, Goldstein SL, Cooper DS, Nelson DP, Morales DL, Krawczeski CD. Peritoneal dialysis vs furosemide for prevention of fluid overload in infants after cardiac surgery: a randomized clinical trial. JAMA Pediatr. 2017;171(4):357–64.

    Article  PubMed  Google Scholar 

  90. Kuo JC, Craft PS. Administration of chemotherapy in patients on dialysis. Anti-Cancer Drugs. 2015;26(7):779–84.

    Article  CAS  PubMed  Google Scholar 

  91. Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103(12):1815–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Nijstad AL, van Eijkelenburg NKA, Kraal K, Meijs MJM, de Kanter C, Lilien MR, et al. Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis. Cancer Chemother Pharmacol. 2020;86(3):445–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200–e7.

    Article  CAS  PubMed  Google Scholar 

  94. Kishimoto K, Kobayashi R, Sano H, Suzuki D, Yasuda K, Kobayashi K. Analysis of risk factors for hyponatremia during or following chemotherapy in children with cancer: a hospital-based, Retrospective Cohort study. J Pediatr Hematol Oncol. 2016;38(6):443–8.

    Article  CAS  PubMed  Google Scholar 

  95. Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012;17(6):756–65.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Shirali A. Electrolyte and acid–base disorders in malignancy. 2016. In: Onco-Nephrology [Internet]. https://www.asn-online.org/education/distancelearning/curricula/onco/. [1–7].

  97. Filippatos TD, Milionis HJ, Elisaf MS. Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol. 2005;75(6):449–60.

    Article  CAS  PubMed  Google Scholar 

  98. Kerdudo C, Aerts I, Fattet S, Chevret L, Pacquement H, Doz F, et al. Hypercalcemia and childhood cancer: a 7-year experience. J Pediatr Hematol Oncol. 2005;27(1):23–7.

    Article  PubMed  Google Scholar 

  99. Huang TH, Liu HC, Hou JY, Chang CY, Sun FJ, Yeh TC. Efficacy and safety of denosumab therapy for low bone mineral density in childhood cancer survivors: a report of preliminary experience. Pediatr Blood Cancer. 2019;66(10):e27927.

    PubMed  Google Scholar 

  100. Boschee ED, Cave DA, Garros D, Lequier L, Granoski DA, Guerra GG, et al. Indications and outcomes in children receiving renal replacement therapy in pediatric intensive care. J Crit Care. 2014;29(1):37–42.

    Article  PubMed  Google Scholar 

  101. Rosolem MM, Rabello LS, Lisboa T, Caruso P, Costa RT, Leal JV, et al. Critically ill patients with cancer and sepsis: clinical course and prognostic factors. J Crit Care. 2012;27(3):301–7.

    Article  PubMed  Google Scholar 

  102. Thirumala R, Ramaswamy M, Chawla S. Diagnosis and management of infectious complications in critically ill patients with cancer. Crit Care Clin. 2010;26(1):59–91.

    Article  CAS  PubMed  Google Scholar 

  103. Kar YD, Ozdemir ZC, Bor O. Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients. Turk Pediatri Ars. 2017;52(4):213–20.

    PubMed  PubMed Central  Google Scholar 

  104. Sandoval C, Sinaki B, Weiss R, Munoz J, Ozkaynak MF, Tugal O, et al. Urinary tract infections in pediatric oncology patients with fever and neutropenia. Pediatr Hematol Oncol. 2012;29(1):68–72.

    Article  PubMed  Google Scholar 

  105. Lehrnbecher T, Phillips R, Alexander S, Alvaro F, Carlesse F, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30(35):4427–38.

    Article  PubMed  Google Scholar 

  106. Cesaro S, Dalianis T, Hanssen Rinaldo C, Koskenvuo M, Pegoraro A, Einsele H, et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018;73(1):12–21.

    CAS  PubMed  Google Scholar 

  107. Hirsch HH, Randhawa P, Practice ASTIDCo. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):179–88.

    Article  CAS  PubMed  Google Scholar 

  108. Laskin BL, Singh HK, Beier UH, Moatz T, Furth SL, Bunin N, et al. The noninvasive urinary polyomavirus haufen test predicts BK virus nephropathy in children after hematopoietic cell transplantation: a pilot study. Transplantation. 2016;100(10):e81–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Bruno B, Zager RA, Boeckh MJ, Gooley TA, Myerson DH, Huang ML, et al. Adenovirus nephritis in hematopoietic stem-cell transplantation. Transplantation. 2004;77(7):1049–57.

    Article  PubMed  Google Scholar 

  110. Cesaro S, Berger M, Tridello G, Mikulska M, Ward KN, Ljungman P, et al. A survey on incidence and management of adenovirus infection after allogeneic HSCT. Bone Marrow Transplant. 2019;54(8):1275–80.

    Article  PubMed  Google Scholar 

  111. Kizilbash SJ, Kashtan CE, Chavers BM, Cao Q, Smith AR. Acute kidney injury and the risk of mortality in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(7):1264–70.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Ellis MJ, Parikh CR, Inrig JK, Kanbay M, Patel UD. Chronic kidney disease after hematopoietic cell transplantation: a systematic review. Am J Transplant. 2008;8(11):2378–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Gibson TM, Mostoufi-Moab S, Stratton KL, Leisenring WM, Barnea D, Chow EJ, et al. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2018;19(12):1590–601.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Calderon-Margalit R, Pleniceanu O, Tzur D, Stern-Zimmer M, Afek A, Erlich T, et al. Childhood cancer and the risk of ESKD. J Am Soc Nephrol. 2020;32(2):495.

    Article  PubMed  Google Scholar 

  115. Choi M, Sun CL, Kurian S, Carter A, Francisco L, Forman SJ, et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. Cancer. 2008;113(7):1580–7.

    Article  PubMed  Google Scholar 

  116. Cohen E, Drobyski W, Moulder J. Significant increase in end-stage renal disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39(9):571–2.

    Article  CAS  PubMed  Google Scholar 

  117. Béchade C, Dejardin O, Bara S, Bouvier V, Guizard AV, De Mil R, et al. Survival of patients with cancer starting chronic dialysis: data from kidney and cancer registries in lower Normandy. Nephrology. 2018;23(12):1125–30.

    Article  PubMed  Google Scholar 

  118. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354(9173):93–9.

    Article  CAS  PubMed  Google Scholar 

  119. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87(7):3136–41.

    Article  CAS  PubMed  Google Scholar 

  120. Han JW, Kim HS, Hahn SM, Jin SL, Shin YJ, Kim SH, et al. Poor bone health at the end of puberty in childhood cancer survivors. Pediatr Blood Cancer. 2015;62(10):1838–43.

    Article  CAS  PubMed  Google Scholar 

  121. Marcucci G, Beltrami G, Tamburini A, Body JJ, Confavreux CB, Hadji P, et al. Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors. Ann Oncol. 2019;30(6):908–20.

    Article  CAS  PubMed  Google Scholar 

  122. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest. 2012;122(7):2543–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin – an updated overview. Nat Clin Pract Oncol. 2006;3(3):152–64.

    Article  CAS  PubMed  Google Scholar 

  124. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373(9674):1532–42.

    Article  CAS  PubMed  Google Scholar 

  125. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12(12):CD003407.

    PubMed  Google Scholar 

  126. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197–210.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev. 2016;(2):1465–1858.

    Google Scholar 

  128. Durmaz O, Demirkaya M, Sevinir B. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. Pediatr Hematol Oncol. 2011;28(6):461–8.

    Article  CAS  PubMed  Google Scholar 

  129. Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol. 2006;24(22):3583–9.

    Article  CAS  PubMed  Google Scholar 

  130. Büyükpamukçu M, Varan A, Kutluk T, Akyüz C. Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Med Pediatr Oncol. 2002;39(4):455–8.

    Article  PubMed  Google Scholar 

  131. Marec-Berard P, Chastagner P, Kassab-Chahmi D, Casadevall N, Marchal C, Misset JL, et al. 2007 standards, options, and recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. Pediatr Blood Cancer. 2009;53(1):7–12.

    Article  PubMed  Google Scholar 

  132. Hazzan AD, Shah HH, Hong S, Sakhiya V, Wanchoo R, Fishbane S. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer. Kidney Int. 2014;86(1):34–9.

    Article  CAS  PubMed  Google Scholar 

  133. Grigoriev Y, Lange J, Peterson SM, Takashima JR, Ritchey ML, Ko D, et al. Treatments and outcomes for end-stage renal disease following Wilms tumor. Pediatr Nephrol. 2012;27(8):1325–33.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Oliver MJ, Garg AX, Blake PG, Johnson JF, Verrelli M, Zacharias JM, et al. Impact of contraindications, barriers to self-care and support on incident peritoneal dialysis utilization. Nephrol Dial Transplant. 2010;25(8):2737–44.

    Article  PubMed  Google Scholar 

  135. Sheth RD, Brandt ML, Brewer ED, Nuchtern JG, Kale AS, Goldstein SL. Permanent hemodialysis vascular access survival in children and adolescents with end-stage renal disease. Kidney Int. 2002;62(5):1864–9.

    Article  PubMed  Google Scholar 

  136. Jeong S, Kwon H, Chang JW, Han Y, Kwon TW, Cho YP. Outcomes of arteriovenous access among cancer patients requiring chronic haemodialysis. BMC Nephrol. 2020;21(1):297.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Goldstein SL, Graham N, Burwinkle T, Warady B, Farrah R, Varni JW. Health-related quality of life in pediatric patients with ESRD. Pediatr Nephrol. 2006;21(6):846–50.

    Article  PubMed  Google Scholar 

  138. Dietz AC, Seidel K, Leisenring WM, Mulrooney DA, Tersak JM, Glick RD, et al. Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2019;20(10):1420–31.

    Article  PubMed  PubMed Central  Google Scholar 

  139. Serrano OK, Gannon A, Olowofela AS, Reddy A, Berglund D, Matas AJ. Long-term outcomes of pediatric kidney transplant recipients with a pretransplant malignancy. Pediatr Transplant. 2019;23(7):e13557.

    Article  PubMed  Google Scholar 

  140. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant. 1997;2(4):14–7.

    CAS  PubMed  Google Scholar 

  141. Watschinger B, Budde K, Crespo M, Heemann U, Hilbrands L, Maggiore U, et al. Pre-existing malignancies in renal transplant candidates – time to reconsider waiting times. Nephrol Dial Transplant. 2019;34(8):1292–300.

    Article  PubMed  Google Scholar 

  142. Brattström C, Granath F, Edgren G, Smedby KE, Wilczek HE. Overall and cause-specific mortality in transplant recipients with a pretransplantation cancer history. Transplantation. 2013;96(3):297–305.

    Article  PubMed  Google Scholar 

  143. Vogelzang JL, van Stralen KJ, Noordzij M, Diez JA, Carrero JJ, Couchoud C, et al. Mortality from infections and malignancies in patients treated with renal replacement therapy: data from the ERA-EDTA registry. Nephrol Dial Transplant. 2015;30(6):1028–37.

    Article  PubMed  Google Scholar 

  144. Aronoff GM, Bennett WM, Berns JS, et al. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia: American College of Physicians; 2007.

    Google Scholar 

  145. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21(1):33–64.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Seattle Children’s Hospital/University of Washington, Seattle, WA, USA

    Russell S. Whelan & Sangeeta R. Hingorani

  2. Division of Nephrology, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Benjamin L. Laskin

Authors
  1. Russell S. Whelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin L. Laskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sangeeta R. Hingorani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sangeeta R. Hingorani .

Editor information

Editors and Affiliations

  1. Division of Nephrology, Bambino Gesù Children’s Hospital –, ROMA, Roma, Italy

    Francesco Emma

  2. Division of Nephrology and Hypertension The Heart Institute, University of Cincinnati Cincinnati Children’s Hospital Medical C, Cincinnati, OH, USA

    Stuart Goldstein

  3. Division of Nephrology, All India Institute of Medical Sciences, Ansari Nagar East, Delhi, India

    Arvind Bagga

  4. Division of Pediatric Nephrology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

    Carlton M. Bates

  5. Renal Unit, Graet Ormond Street Hospital, London, UK

    Rukshana Shroff

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Germany, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Whelan, R.S., Laskin, B.L., Hingorani, S.R. (2021). Onconephrology. In: Emma, F., Goldstein, S., Bagga, A., Bates, C.M., Shroff, R. (eds) Pediatric Nephrology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27843-3_122-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-27843-3_122-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-27843-3

  • Online ISBN: 978-3-642-27843-3

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation